Green Thumb Industries (OTCMKTS:GTBIF) closed its third quarter of 2026 with record revenue of $324.4 million, up 11.3% year over year, driven in large part by adult-use sales ramping in Minnesota. That top-line strength arrives alongside a net loss of $4.8 million and a stock price down nearly 9% over the past year - a split picture that captures where the multi-state operator sits heading into 2027.
Minnesota Lift Masks Margin Pressure
Retail revenue rose 10.1% year over year, with same-store sales up 3%, and consumer packaged goods revenue climbed 16%, again tied to Minnesota's new adult-use channel. That's the good news. The less tidy part: gross margin slipped to 45.2% from 49.4% a year earlier, even as gross profit grew. For a multi-state operator, that kind of margin compression often traces back to wholesale pricing pressure, new-market launch costs, and the compliant packaging and lab-testing overhead that comes with opening fresh retail footprint. Six new stores opened in the quarter - two in Florida, one in Nevada, three in Pennsylvania - and three more in Florida since. Store count now stands at 130. Expansion costs money before it generates steady-state margin, and that lag shows up directly in the income statement.
Rescheduling and State-Level Reform Reshape the Calculus
The DEA is expected to issue a final ruling on recreational cannabis rescheduling by year-end, a development operators have been positioning around for months. Green Thumb has already registered its medical operations with the DEA and begun claiming business deductions tied to that status - a meaningful shift for any cannabis operator previously boxed in by Section 280E, which bars standard business expense deductions for companies trafficking in federally controlled substances. Full rescheduling of recreational cannabis, if finalized, would extend that relief further and materially change after-tax cash flow across the sector.
There's also a legislative angle. A changed Senate and Congress composition raises the odds, however modest, of federal cannabis banking protections or broader legalization measures advancing. Texas is worth watching too: a new governor could open the door to decriminalization or medical-market expansion, and Green Thumb is already preparing to enter Texas medical cannabis. None of this is guaranteed. Cannabis policy has a long history of stalling in committee, and operators who build forecasts around pending legislation tend to get burned. Still, the combination of DEA action, state-level movement, and a 2027 recreational launch in Virginia - where Green Thumb already runs medical dispensaries - gives the company more near-term catalysts than most peers can point to.
Balance Sheet Strength Versus Sector Volatility
The fundamentals here are not in question. Cash and short-term investments sit at $316.0 million against total debt of $277.3 million, operating cash flow came in at $58.3 million for the quarter, and total assets exceed total liabilities by a comfortable margin. The stock trades below both book value per share and net asset value per share, and trailing EV/Revenue multiples point toward undervaluation relative to the company's own balance sheet. In practice, though, valuation metrics only matter if the market is willing to re-rate the sector, and right now it isn't. Midterm election fallout and broader macro volatility have weighed on cannabis equities broadly, and that pressure shows no sign of lifting on its own timeline.
Among peers, Curaleaf holds the revenue lead, helped by international sales, while Green Thumb runs second. Trulieve has outperformed on stock price after divesting certain recreational assets and uplisting to the NYSE, a move other multi-state operators appear to be studying. For dispensary operators and wholesale partners watching from outside the public markets, the signal is this: even companies with strong same-store sales, growing CPG revenue, and disciplined balance sheets remain hostage to sector sentiment and policy timing they don't control.
What Comes Next
- DEA rescheduling ruling expected by year-end, with direct implications for 280E tax treatment
- Virginia adult-use sales launching in 2027, building on existing medical dispensary infrastructure
- Texas medical market entry in preparation
- Q4 revenue consensus at $313.15 million, down sequentially but up year over year
A Hold rating reflects this split picture fairly. The operational story is sound, and the policy tailwinds are real, if unfinished. The sector's volatility, though, is the part nobody can forecast with confidence, and that's reason enough for caution rather than conviction in either direction.
